MBOT Stock - Microbot Medical Inc.
Unlock GoAI Insights for MBOT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-91,000 | $-106,000 | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-11,625,000 | $-9,855,000 | $-13,281,000 | $-11,357,000 | $-9,089,000 |
| Net Income | $-11,443,000 | $-10,740,000 | $-13,168,000 | $-11,313,000 | $-9,169,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.73 | $-1.05 | $-1.81 | $-1.59 | $-1.29 |
Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company, through its ViRob, TipCAT, CardioSert, and Liberty micro-robotic technologies, developing Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; a disposable robot for various endovascular interventional procedures; and a multi generation pipeline portfolio. It has 42 issued/allowed patents and 23 patent applications pending worldwide. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 3rd 2025 | Roth Capital | Initiation | Buy | $5.5 |
Earnings History & Surprises
MBOTEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 24, 2026 | $-0.07 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.06 | $-0.07 | -16.7% | ✗ MISS |
Q3 2025 | Aug 12, 2025 | $-0.08 | $-0.10 | -25.0% | ✗ MISS |
Q2 2025 | May 14, 2025 | $-0.13 | $-0.08 | +38.5% | ✓ BEAT |
Q1 2025 | Mar 25, 2025 | $-0.18 | $-0.20 | -11.1% | ✗ MISS |
Q4 2024 | Nov 13, 2024 | $-0.17 | $-0.20 | -17.6% | ✗ MISS |
Q3 2024 | Aug 14, 2024 | $-0.17 | $-0.17 | 0.0% | = MET |
Q2 2024 | May 15, 2024 | $-0.17 | $-0.17 | 0.0% | = MET |
Q1 2024 | Mar 27, 2024 | $-0.25 | $-0.26 | -4.0% | ✗ MISS |
Q4 2023 | Nov 14, 2023 | $-0.25 | $-0.21 | +16.0% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | $-0.31 | $-0.25 | +19.4% | ✓ BEAT |
Q1 2023 | Mar 31, 2023 | $-0.45 | $-0.38 | +15.6% | ✓ BEAT |
Q1 2023 | Mar 29, 2023 | $-0.47 | $-0.54 | -14.9% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | $-0.51 | $-0.49 | +3.9% | ✓ BEAT |
Q3 2022 | Aug 15, 2022 | $-0.45 | $-0.49 | -8.9% | ✗ MISS |
Q2 2022 | May 16, 2022 | $-0.42 | $-0.45 | -7.1% | ✗ MISS |
Q1 2022 | Mar 31, 2022 | $-0.54 | $-0.54 | 0.0% | = MET |
Q4 2021 | Nov 15, 2021 | $-0.36 | $-0.36 | 0.0% | = MET |
Q3 2021 | Aug 16, 2021 | $-0.35 | $-0.35 | 0.0% | = MET |
Q2 2021 | May 17, 2021 | $-0.33 | $-0.34 | -3.0% | ✗ MISS |
Latest News
Roth Capital Initiates Coverage On Microbot Medical with Buy Rating, Announces Price Target of $5.5
📈 PositiveHC Wainwright & Co. Reiterates Buy on Microbot Medical, Maintains $12 Price Target
📈 PositiveMicrobot Medical Says Emory University Hospital Adopts LIBERTY For Patient Care; Microbot Collaborates With Emory To Establish Endovascular Robotics Program In Interventional Radiology
📈 PositiveMicrobot Medical Announces Commercial Availability Of LIBERTY Robotic System In U.S.
📈 PositiveMicrobot Medical Announces It Will Exhibit Its Liberty Endovascular Robotic System At Symposium On Clinical Interventional Oncology In Miami, Fl, October 17-19, 2025, Marking First Commercial Exhibition Of The System Following Its FDA 510(K) Clearance In September 2025
📈 PositiveHC Wainwright & Co. Reiterates Buy on Microbot Medical, Maintains $12 Price Target
📈 PositiveMicrobot Medical Partners With U.S. Based 3PL Company To Support Commercialization Of FDA-Cleared LIBERTY System
📈 PositiveMicrobot Medical Announces That The Japanese Patent Office Has Granted The Company Its First Patent In Japan, Covering The Core LIBERTY System Technology
📈 PositiveMicrobot Medical Enters Into Agreements To Purchase Up To 13,989,115 Shares Of Common Stock In Two Tranches For Up To $92.2M In Gross Proceeds
📈 PositiveHC Wainwright & Co. Maintains Buy on Microbot Medical, Raises Price Target to $12
📈 PositiveMicrobot Medical shares are trading higher after the company announced that the FDA granted the company 510(k) clearance for the LIBERTY System.
📈 PositiveMicrobot Medical Receives FDA 510(k) Clearance For LIBERTY Robotic System, Targets Q4 2025 Commercial Launch
📈 PositiveMicrobot Medical Option Alert: Jan 16 $2.5 Calls at the Ask: 20000 @ $2.05 vs 39143 OI; Ref=$4.525
📈 PositiveMicroMedical shares are trading higher. The stock may be moving on continued strength after the company announced that the U.S. Patent and Trademark Office has granted it a patent covering robotic surgical systems on Wednesday.
📈 PositiveUS Patent And Trademark Office Grants Microbot Medical Patent Covering Modular Robotic Surgical System Includes Base And Plurality Of Tool-Receiver Units Arranged As Separate Units And Independently And Interchangeably Attachable To Base
📈 PositiveFrequently Asked Questions about MBOT
What is MBOT's current stock price?
What is the analyst price target for MBOT?
What sector is Microbot Medical Inc. in?
What is MBOT's market cap?
Does MBOT pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to MBOT for comparison